Majority of Patients with C Diff Willing to Use Rectally Adm

Survey results showed patients with a history of live biotherapeutic product therapy preferred rectally administered treatment while patients who had not received live biotherapeutic product therapy would be willing to consider it.

Related Keywords

, Paul Feuerstadt , Centers For Disease , Us Centers For Disease , Yale School Of Medicine , Yale School Of Medicine Paul Feuerstadt , Yale School , Disease Control , Van Hise , Rectal Administration , Recurrent Clostridioides , Patient Prefer , Accessed September , Clotridoides Difficile Infection , C Diff , Ccdi , Fecal Microbiota Transplantation , Cfmt , Live Biotherapeutic Product , Lbp ,